The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical laboratory publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) Center for Devices and Radiological Health, European Medicines Agency (EMA) In Vitro Diagnostic Regulation (IVDR), Centers for Medicare & Medicaid Services (CMS), Centers for Disease Control and Prevention (CDC) Laboratory Division, National Institutes of Health (NIH), World Health Organization (WHO) Global Health Observatory and Essential Diagnostics List, ClinicalTrials.gov, National Center for Biotechnology Information (NCBI/PubMed), Agency for Healthcare Research and Quality (AHRQ), European Centre for Disease Prevention and Control (ECDC), EU Eurostat Health Database, and national health ministry reports from key markets. These sources were used to collect diagnostic testing statistics, regulatory approval data (510(k), PMA, CE-IVD), clinical safety and efficacy studies, laboratory automation trends, and market landscape analysis for immunoassay platforms, molecular diagnostics (PCR/NGS), clinical chemistry analyzers, hematology systems, microbiology testing, and point-of-care devices.
Additional authoritative sources included the American Association for Clinical Chemistry (AACC), Association for Molecular Pathology (AMP), American Society for Clinical Pathology (ASCP), Clinical Laboratory Management Association (CLMA), AdvaMedDx, European Diagnostic Manufacturers Association (EDMA), American Diabetes Association (ADA), and College of American Pathologists (CAP) proficiency testing data.
The following sources provided reimbursement classification (CPT/HCPCS), laboratory accreditation standards, and industry benchmarking data for hospital laboratories, clinical reference labs, and physician office labs. Additionally, they provided procedure volume metrics.
